David E. Lazar - 30 Jul 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Reporting relationship: 10%+ Owner
Issuer ticker: CYCC
Reported as of: 30 Jul 2025
Net transaction value: -$83,430
SEC form: 4
Accepted by SEC: 04 Aug 2025, 19:23:01 UTC
Prior SEC filing: 07 Apr 2025
Next SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 04 Aug 2025.

Key facts

This page summarizes David E. Lazar's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2025, 19:23.

Change

Previous filing in this sequence was filed on 07 Apr 2025.
Current net transaction value: -$83,430.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: 10%+ Owner
Address: PH THE TOWERS, TOWER 200, 30B, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 04 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCC transaction

Common Stock

Sale

Transaction value: $83,430
Shares: -6,750
Change %: -4.2%
Price: $12.36^*
Shares after: 155,838
Date: 30 Jul 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David E. Lazar is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").

Footnote F2

Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.

SEC remarks

This filing constitutes an exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Exchange Act as a result of the sale described above.